Beatriz Morillo-Gutierrez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Beatriz Morillo-Gutierrez has a total of 355 co-authors. Here are the top co-authors by number of shared publications:
- Ignacio Obando
Department of Pediatrics, Hospital Universitario Virgen del Rocío
3 shared publications Mary Slatter
Department of Paediatric Immunology, Great North Children's Hospital, Newcastle upon Tyne, United Kingdom
3 shared publications- Olaf Neth
Sección de Infectología e Inmunopatología, Unidad de Pediatría, Hospital Virgen del Rocío/Instituto de Biomedicina de Sevilla (IBiS), Sevilla, Spain
3 shared publications Andrew Cant
Department of Paediatric Immunology, Newcastle upon Tyne, United Kingdom; Institute of Cellular Medicine, Newcastle upon Tyne University, Newcastle upon Tyne, United Kingdom
2 shared publicationsAndrew R. Gennery
Department of Paediatric Immunology, Great North Children´s Hospital, Newcastle Upon Tyne, United Kingdom; Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom
2 shared publicationsH. Bobby Gaspar
2 shared publications
Latest Publications
- Open Access
- 1 June 2018
- Published by Elsevier in The Lancet Child & Adolescent Health
- Vol. 2 (6) , 404-414
Life-threatening infections in children in Europe (the EUCLIDS Project): a prospective cohort study
- 1 June 2018
- Published by Elsevier in The Lancet Child & Adolescent Health
- Vol. 2 (6) , 404-414
Open AccessLife-threatening infections in children in Europe (the EUCLIDS Project): a prospective cohort study
- 1 January 2018
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 141 (1) , 405-408.e7
Liver disease predicts mortality in patients with X-linked immunodeficiency with hyper-IgM but can be prevented by early hematopoietic stem cell transplantation
- 1 January 2018
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 141 (1) , 405-408.e7
Liver disease predicts mortality in patients with X-linked immunodeficiency with hyper-IgM but can be prevented by early hematopoietic stem cell transplantation
- Open Access
- 22 August 2017
- Published by Springer Nature in BMC Pediatrics
- Vol. 17 (1) , 1-4
Emerging (val)ganciclovir resistance during treatment of congenital CMV infection: a case report and review of the literature
Congenital cytomegalovirus (cCMV) infection is an important illness that is a common cause of hearing loss in newborn infants and a major cause of disability in children. For that reason, treatment of symptomatic patients with either ganciclovir or its pro-drug valganciclovir is recommended. Treatment duration of 6 months has been shown to be more beneficial than shorter courses; however, there is uncertainty regarding emergence of resistance strains, secondary effects and long term sequelae. Here we present a female infant with symptomatic cCMV who was treated from day 5 of life with oral valganciclovir. In spite of close monitoring of her drug levels and increments of her treatment dose according to weight gain, she developed ganciclovir resistance after 4 months of treatment, with increasing viraemia and petechiae. Adherence to treatment was assessed and felt to be good. Clinically, although she had marked developmental delay, she was making steady progress. In view of the development of resistance treatment was stopped at 5 months of age. No secondary effects of ganciclovir were noted during the whole course. There were few cases in the literature reporting resistance to ganciclovir for cCMV before the new recommendations for a 6 months treatment course for this infection were published. As demonstrated in our patient, surveillance with periodic viral loads and drug monitoring are vital to identify emerging resistance and optimise antiviral dosing according to weight gain.
- 22 August 2017
- Published by Springer Nature in BMC Pediatrics
- Vol. 17 (1) , 1-4
Open AccessEmerging (val)ganciclovir resistance during treatment of congenital CMV infection: a case report and review of the literature
Congenital cytomegalovirus (cCMV) infection is an important illness that is a common cause of hearing loss in newborn infants and a major cause of disability in children. For that reason, treatment of symptomatic patients with either ganciclovir or its pro-drug valganciclovir is recommended. Treatment duration of 6 months has been shown to be more beneficial than shorter courses; however, there is uncertainty regarding emergence of resistance strains, secondary effects and long term sequelae. Here we present a female infant with symptomatic cCMV who was treated from day 5 of life with oral valganciclovir. In spite of close monitoring of her drug levels and increments of her treatment dose according to weight gain, she developed ganciclovir resistance after 4 months of treatment, with increasing viraemia and petechiae. Adherence to treatment was assessed and felt to be good. Clinically, although she had marked developmental delay, she was making steady progress. In view of the development of resistance treatment was stopped at 5 months of age. No secondary effects of ganciclovir were noted during the whole course. There were few cases in the literature reporting resistance to ganciclovir for cCMV before the new recommendations for a 6 months treatment course for this infection were published. As demonstrated in our patient, surveillance with periodic viral loads and drug monitoring are vital to identify emerging resistance and optimise antiviral dosing according to weight gain.
- Open Access
- 17 April 2017
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 37 (5) , 415-418
Disseminated Mycobacterium malmoense and Salmonella Infections Associated with a Novel Variant in NFKBIA
- 17 April 2017
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 37 (5) , 415-418
Open AccessDisseminated Mycobacterium malmoense and Salmonella Infections Associated with a Novel Variant in NFKBIA
- 1 August 2016
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 138 (2) , 603-605.e1
Haploidentical CD3 TCRαβ and CD19-depleted second stem cell transplant for steroid-resistant acute skin graft versus host disease
- 1 August 2016
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 138 (2) , 603-605.e1
Haploidentical CD3 TCRαβ and CD19-depleted second stem cell transplant for steroid-resistant acute skin graft versus host disease
- Open Access
- 21 July 2016
- Published by American Society of Hematology in Blood
- Vol. 128 (3) , 440-448
Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience
Key Points: Treosulfan, a low-toxicity alkylating agent, can be used effectively as part of conditioning for HSCT in children with CGD. Long-term follow-up is required to ascertain effects, particularly on gonadal function and compare with other regimens.
- 21 July 2016
- Published by American Society of Hematology in Blood
- Vol. 128 (3) , 440-448
Open AccessTreosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience
Key Points: Treosulfan, a low-toxicity alkylating agent, can be used effectively as part of conditioning for HSCT in children with CGD. Long-term follow-up is required to ascertain effects, particularly on gonadal function and compare with other regimens.
- 1 September 2015
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 34 (9) , 1040-1041
Chronic Infection with Rotavirus Vaccine Strains in UK Children with Severe Combined Immunodeficiency
- 1 September 2015
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 34 (9) , 1040-1041
Chronic Infection with Rotavirus Vaccine Strains in UK Children with Severe Combined Immunodeficiency
- Open Access
- 1 August 2015
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 136 (2) , 502-505.e4
A new case of Fas-associated death domain protein deficiency and update on treatment outcomes
- 1 August 2015
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 136 (2) , 502-505.e4
Open AccessA new case of Fas-associated death domain protein deficiency and update on treatment outcomes
- Open Access
- 1 July 2014
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 134 (1) , 215-218.e3
Immunodeficiency and disseminated mycobacterial infection associated with homozygous nonsense mutation of IKKβ
- 1 July 2014
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 134 (1) , 215-218.e3
Open AccessImmunodeficiency and disseminated mycobacterial infection associated with homozygous nonsense mutation of IKKβ
- Open Access
- 1 August 2012
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 18 (8) , 763-768
Sustained high prevalence of pneumococcal serotype 1 in paediatric parapneumonic empyema in southern Spain from 2005 to 2009
- 1 August 2012
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 18 (8) , 763-768
Open AccessSustained high prevalence of pneumococcal serotype 1 in paediatric parapneumonic empyema in southern Spain from 2005 to 2009